Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Single amino acid–based PROTACs trigger degradation of the oncogenic kinase BCR–ABL in chronic myeloid leukemia (CML)
Jianchao Zhang, Caibing Ma, Yongjun Yu, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 8, pp. 104994-104994
Open Access | Times Cited: 12

Showing 12 citing articles:

N-degron pathways
Alexander Varshavsky
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 39
Open Access | Times Cited: 8
Exploration of Degrons and Their Ability to Mediate Targeted Protein Degradation
Timothy J. Harris, Darci J. Trader
RSC Medicinal Chemistry (2025)
Closed Access
Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
Zhuo Qian, Yi‐Ru Bai, Wenjuan Zhou, et al.
Bioorganic Chemistry (2025) Vol. 156, pp. 108189-108189
Closed Access
Structure‐guided drug design targeting Abl kinase: how structure and regulation can assist in designing new drugs
Diego Martins, Philipe Oliveira Fernandes, Lucas A. Vieira, et al.
ChemBioChem (2024)
Closed Access | Times Cited: 2
Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC)
Jianchao Zhang, Xiao Chen, Congli Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13666-13680
Closed Access | Times Cited: 1
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
M. Malarvannan, S. Unnikrishnan, S. Monohar, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 107984-107984
Closed Access | Times Cited: 1
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph+ leukemias?
Nataly Cruz-Rodríguez, Hua Tang, Benjamin Bateman, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1885-1893
Open Access | Times Cited: 1
Mini PROTACs: N-end rule-mediated degradation on the horizon
Yanfen Liu, Zhangshun Wang, Yong Cang
Trends in Biochemical Sciences (2023) Vol. 49, Iss. 1, pp. 5-7
Closed Access | Times Cited: 3
The ubiquitin ligase UBR4 and the deubiquitylase USP5 modulate the stability of DNA mismatch repair protein MLH1
Chenyu Mao, Siqi Li, Jun Che, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 8, pp. 107592-107592
Closed Access
Page 1

Scroll to top